On November 2, 2020, the second day of immune research of the Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD took place. 120 experts from 26 Fraunhofer institutes as well as from universities, university hospitals and industry took part in the virtual event. PD dr Thomas Grunwald, head of the Preclinical Validation working group at the Fraunhofer Institute for Cell Therapy and Immunology IZI, presented the work on the development of a vaccination against asthma.
There are currently no approved vaccines against respiratory syncytial virus (RSV). As part of the project, various vaccines are to be tested that are administered mucosally – i.e. via a nasal spray or inhalation. On the one hand, an inactivated vaccine is used in which the viruses are inactivated using low-energy electron beams. This vaccine is to be packaged in nanoparticles, among other things, to enable increased absorption through the mucous membranes. Another vaccine used is DNA that encodes RSV-F, the main RSV antigen. This DNA is packaged in non-human papilloma viruses and applied with the help of these gene shuttles. The aim is to develop a mucosal application of RSV antigens to prevent juvenile bronchial asthma.
In the Cluster of Excellence for Immune-Mediated Diseases CIMD established in 2018, Fraunhofer IZI works with the Fraunhofer Institutes for Molecular Biology and Applied Ecology IME and for Toxicology and Experimental Medicine ITEM. Fraunhofer CIMD is dedicated to translational research. It thus transfers basic research into application in the four major subject areas of health research - drugs, diagnostics, devices and data.